mda

Nelonemdaz (Neu2000) is an NMDA receptor antagonist with antioxidant activity and neuroprotective activity used in the study of cerebral infarction reperfusion injury and acute ischemic stroke.

N-Methyl-D-aspartic acid is an amino acid that, as the D-isomer, is the defining agonist for the NMDA (N-Methyl-D-aspartic acid) receptor subtype of glutamate receptors.

NMDA-IN-1 is a potent and NR2B-selective antagonist of NMDA, with an NMDA Ki of 0.85 nM and an NR2B Ca2+ influx IC50 of 9.7 nM.

Rislenemdaz (CERC-301) (CERC-301) is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B).

DMDA-PatA is a small-molecule inhibitor of eIF4A, a DEAD-box RNA-binding protein. It functions by clamping eIF4A onto the GNG motif in an mRNA-selective and ATP-independent manner, thereby inhibiting translation. DMDA-PatA holds potential for applications in cancer and viral infection research.

MDA77 is a CB2 agonist with an EC50 value of 5.82 nM and exhibits no activity towards CB1.

NMDAR antagonist 2 (compound 3I) is a blood-brain barrier permeable antagonist of NMDA receptors, exhibiting IC50 values of 4.42 μM and 214.75 μM at membrane potentials of -60 mV and 40 mV, respectively, for hGluN1 hGluN2A. This compound has been shown to mitigate hippocampal damage.

NMDA agonist 1 (compound 42d) is a potent NMDA agonist with a Ki value of 96 nM. It acts as a partial agonist of the GluN1 GluN2B complex, exhibiting an EC50 value of 78 nM.

NMDA agonist 2 (compound 8d) effectively inhibits NMDA receptors, exhibiting an EC50 of 0.034 μM for GluN1 2C. It plays a significant role in neurological and psychiatric disorders.

MDA7 is a selective agonist of the cannabinoid receptor 2 (CB2), demonstrating an EC50 of 128 nM in human CB2 receptors and 67.4 nM in rat CB2 receptors. The compound exhibits good affinity for CB2 receptors, with Ki values of 422 nM for humans and 238 nM for rats. In rat models, MDA7 shows analgesic activity.

NMDA caged with the photosensitive 4-methoxy-7-nitroindolinyl group

PMPA (NMDA antagonist) is a Competitive NMDA receptor antagonist.

NMDA receptor antagonist 2 is a highly potent and orally active NR2B subtype-selective antagonist of the N-methyl-D-aspartate (NMDA) receptor, with an IC50 of 1.0 nM and a Ki value of 0.88 nM. This compound is valuable in scientific investigations of neuropathic pain and Parkinson's disease.

Nelonemdaz potassium (also known as Salfaprodil) is a potent NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). This compound exhibits remarkable neuroprotection against cell death induced by both NMDA and free radicals, in addition to its role as a free radical scavenger.

NMDAR antagonist 1 is an orally active, NR2B-selective NMDAR antagonist.

NMDA receptor antagonist 4 (IIc) is an uncompetitive, voltage-dependent, orally active NMDAR blocker with an IC50 of 1.93 μM. It shows positive predicted blood-brain-barrier (BBB) permeability and can be used in Alzheimer's disease research[1].

NMDA-IN-2 (compound 6b) is a Procaine derivative that is an inhibitor of NMDA receptor 2B subtype [1].

NMDA receptor modulator 2 (Compound 1) is a potent NMDA receptor modulator suitable for neurological disorder research [1].

NMDA receptor modulator 3 (Compound 99) is a potent NMDA receptor modulator useful in neurological disorder research [1].

NMDA receptor antagonist-3 is a NMDA receptor antagonist with a significan recovery rate (40.0%, at 100 μM) and safe toxicological characteristics in SH-SY5Y and human adipose mesenchymal stem cells.

NMDA receptor modulator 4 (Compound 169) is a potent NMDA receptor modulator used for neurological disorder research [1].

NMDA receptor modulator 5 (Compound 195), a potent NMDA receptor modulator, shows promise for neurological disorder research [1].

NMDAR HDAC-IN-1 (Compound 9d) is a potent dual inhibitor of N-methyl-D-aspartate receptors (NMDARs) and histone deacetylases (HDACs), with a high affinity for NMDARs (Ki = 0.59 μM) and significant inhibitory effects on various HDAC isoforms, including HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 with IC50 values of 2.67 μM, 8.00 μM, 2.21 μM, 0.18 μM, and 0.62 μM, respectively; additionally, it efficiently crosses the blood-brain barrier [1].

NMDA receptor antagonist 5 (Compound 10e), a potent and non-toxic agent with brain permeability, is significant for studying neurological disorders [1].